- Home
- GPRE vs PHAT Comparison
GPRE vs PHAT Comparison
Compare GPRE & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GPRE | PHAT |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 812.2M | 894.0M |
| IPO Year | 2004 | 2019 |
Fundamental Metrics
Financial Performance| Metric | GPRE | PHAT |
|---|---|---|
| Price | $15.67 | $11.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | $12.57 | ★ $19.83 |
| AVG Volume (30 Days) | 1.3M | ★ 1.4M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $2,091,680,000.00 | $175,110,000.00 |
| Revenue This Year | N/A | $93.04 |
| Revenue Next Year | $11.85 | $58.91 |
| P/E Ratio | $38.63 | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $3.97 | $3.70 |
| 52 Week High | $18.94 | $18.31 |
Technical Indicators
Market Signals| Indicator | GPRE | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 42.43 | 48.19 |
| Support Level | $14.84 | $11.04 |
| Resistance Level | $16.80 | $13.03 |
| Average True Range (ATR) | 0.92 | 0.81 |
| MACD | -0.20 | -0.11 |
| Stochastic Oscillator | 3.55 | 32.59 |
Price Performance
Historical ComparisonAbout GPRE Green Plains Inc.
Green Plains Inc manufactures and sells ethanol and ethanol byproducts in two segments based on function. The ethanol production segment, which generates the majority of revenue, includes the production of ethanol, distillers grains, Ultra-High Protein and renewable corn oil. The agribusiness and energy services segment includes grain handling and storage, commodity marketing and merchant trading for company-produced and third-party ethanol, distillers grains, Ultra-High Protein, renewable corn oil, natural gas and other commodities.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.